0211 regeneron HoFH approval
BioCentury & Getty Images


FDA approval of Regeneron’s Evkeeza brings new drug class to HoFH patients

Feb 12, 2021 | 2:06 AM GMT

Regeneron’s Evkeeza evinacumab-dgnb gained FDA approval Thursday as the first ANGPTL3 inhibitor to treat homozygous familial hypercholesterolemia,

Read the full 389 word article

How to gain access

Continue reading with a
two-week free trial.